213 related articles for article (PubMed ID: 8468271)
21. Second malignancy complicating Hodgkin's disease.
Tawil E; Mercier JP
J Can Assoc Radiol; 1983 Jun; 34(2):108-13. PubMed ID: 6688422
[TBL] [Abstract][Full Text] [Related]
22. [The management of Hodgkin's disease with chemotherapy or combined modality treatment].
Tsushita K; Utsumi M; Shimoyama M
Gan To Kagaku Ryoho; 1998 Dec; 25(14):2202-9. PubMed ID: 9881076
[TBL] [Abstract][Full Text] [Related]
23. Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease.
Tebbi CK; London WB; Friedman D; Villaluna D; De Alarcon PA; Constine LS; Mendenhall NP; Sposto R; Chauvenet A; Schwartz CL
J Clin Oncol; 2007 Feb; 25(5):493-500. PubMed ID: 17290056
[TBL] [Abstract][Full Text] [Related]
24. Long-term events in adult patients with clinical stage IA-IIA nonbulky Hodgkin's lymphoma treated with four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine and adjuvant radiotherapy: a single-institution 15-year follow-up.
Brusamolino E; Baio A; Orlandi E; Arcaini L; Passamonti F; Griva V; Casagrande W; Pascutto C; Franchini P; Lazzarino M
Clin Cancer Res; 2006 Nov; 12(21):6487-93. PubMed ID: 17085663
[TBL] [Abstract][Full Text] [Related]
25. Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials.
Noordijk EM; Carde P; Dupouy N; Hagenbeek A; Krol AD; Kluin-Nelemans JC; Tirelli U; Monconduit M; Thomas J; Eghbali H; Aleman BM; Bosq J; Vovk M; Verschueren TA; Pény AM; Girinsky T; Raemaekers JM; Henry-Amar M
J Clin Oncol; 2006 Jul; 24(19):3128-35. PubMed ID: 16754934
[TBL] [Abstract][Full Text] [Related]
26. Survival and late effects in children with Hodgkin's lymphoma treated with MOPP/ABV and low-dose, extended-field irradiation.
Chow LM; Nathan PC; Hodgson DC; Jenkin D; Weitzman S; Grant RM; Manson D; Bross A; Doyle JJ; Danjoux C; Greenberg ML
J Clin Oncol; 2006 Dec; 24(36):5735-41. PubMed ID: 17179107
[TBL] [Abstract][Full Text] [Related]
27. [Outcome of 70 patients diagnosed with Hodgkin's disease after first-line and salvage treatment: experience at one center].
Arranz R; Gil-Fernández JJ; Muñoz E; Acevedo A; Sobrino MP; Fernández-Rañada JM
Sangre (Barc); 1998 Jun; 43(3):179-84. PubMed ID: 9741222
[TBL] [Abstract][Full Text] [Related]
28. Secondary leukemia and myelodysplastic syndrome after treatment for Hodgkin's disease.
Hoppe RT
Leukemia; 1992 Nov; 6 Suppl 4():155-7. PubMed ID: 1434819
[No Abstract] [Full Text] [Related]
29. [Hodgkin's lymphoma and secondary leukemias].
Centurioni R; Brianzoni MF; Salvi A; Montillo M; Rupoli S; Olivieri A; Leoni P; Danieli G
Recenti Prog Med; 1993 May; 84(5):328-35. PubMed ID: 8511392
[TBL] [Abstract][Full Text] [Related]
30. [Acute leukemia in patients treated for Hodgkin's disease].
Boccaccio P; Rosa F; Casciaro S; D'Elia P; Romagnoli M; Ghio R
Recenti Prog Med; 1988 Jan; 79(1):32-7. PubMed ID: 3375542
[No Abstract] [Full Text] [Related]
31. [Cured from Hodgkin's disease].
Brice P
Bull Cancer; 2002; 89(7-8):666-70. PubMed ID: 12206979
[TBL] [Abstract][Full Text] [Related]
32. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E
Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727
[TBL] [Abstract][Full Text] [Related]
33. Incidence of acute nonlymphocytic leukemia, preleukemia, and acute myeloproliferative syndrome up to 10 years after treatment of Hodgkin's disease.
Pedersen-Bjergaard J; Larsen SO
N Engl J Med; 1982 Oct; 307(16):965-71. PubMed ID: 7110299
[TBL] [Abstract][Full Text] [Related]
34. Second acute leukemia and other malignancies following treatment for Hodgkin's disease.
Valagussa P; Santoro A; Fossati-Bellani F; Banfi A; Bonadonna G
J Clin Oncol; 1986 Jun; 4(6):830-7. PubMed ID: 3711960
[TBL] [Abstract][Full Text] [Related]
35. Secondary malignancies after therapy of indolent non-Hodgkin's lymphoma.
Friedberg JW
Haematologica; 2008 Mar; 93(3):336-8. PubMed ID: 18310538
[No Abstract] [Full Text] [Related]
36. Second primary cancers in patients continuously disease-free from Hodgkin's disease: a protective role for the spleen?
Dietrich PY; Henry-Amar M; Cosset JM; Bodis S; Bosq J; Hayat M
Blood; 1994 Aug; 84(4):1209-15. PubMed ID: 8049435
[TBL] [Abstract][Full Text] [Related]
37. Decreasing risk of leukemia with prolonged follow-up after chemotherapy and radiotherapy for Hodgkin's disease.
N Engl J Med; 1987 Sep; 317(11):707-9. PubMed ID: 3627177
[No Abstract] [Full Text] [Related]
38. [Treatment results of stage IA Hodgkin lymphoma: a report of 97 cases].
Tan WY; Hu DS; Zeng FY; Song QB; Hu S; Wei L; Zhou LQ
Ai Zheng; 2007 Dec; 26(12):1360-4. PubMed ID: 18076802
[TBL] [Abstract][Full Text] [Related]
39. Second malignancies in young children with primary brain tumors following treatment with prolonged postoperative chemotherapy and delayed irradiation: a Pediatric Oncology Group study.
Duffner PK; Krischer JP; Horowitz ME; Cohen ME; Burger PC; Friedman HS; Kun LE
Ann Neurol; 1998 Sep; 44(3):313-6. PubMed ID: 9749596
[TBL] [Abstract][Full Text] [Related]
40. Leukemias and myelodysplastic syndromes secondary to drug, radiation, and environmental exposure.
Levine EG; Bloomfield CD
Semin Oncol; 1992 Feb; 19(1):47-84. PubMed ID: 1736370
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
